Additional Considerations in the Treatment of Diabetic Nephropathy Based on the KDOQI Clinical Practice Guideline
PDF

Keywords

Diabetes Mellitus
Diabetic Nephropathies
obesity
risk factors.
Kidney Diseases

How to Cite

1.
Rico Fontalvo J, Montejo Hernández JD, Daza Arnedo R, Cabrales J. Additional Considerations in the Treatment of Diabetic Nephropathy Based on the KDOQI Clinical Practice Guideline . Rev. Colomb. Nefrol. [Internet]. 2022 Oct. 26 [cited 2022 Nov. 26];9(3). Available from: https://revistanefrologia.org/index.php/rcn/article/view/602

Abstract

Obesity is a risk factor for the development and progression of CKD, which has been shown in numerous studies. The mechanism of how this occurs is not completely understood, but several putative mechanisms proposed via adiposity, include low adiponectin high leptin and resistin, causing inflammation, insulin resistance, RAAS activation and oxidative stress, leading to CKD; in addition, it also causes diabetes mellitus, hypertension, and cardiovascular disease. Obesity is a persistent inflammatory state, and inflammation has been shown to play an important role in the development and progression of diabetic kidney disease, hence controlling obesity has become a key component as a preventative strategy in the development of kidney disease.

 

https://doi.org/10.22265/acnef.9.3.602
PDF

References

Kovesdy CP, Furth SL, Zoccali C. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Canadian Journal of Kidney Health and Disease. 2017; 4. https://doi.org/10.1177/2054358117698669

Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, et al. Molecular Mechanisms of Diabetic Kidney

Disease. Int. J. Mol. Sci. 2022;2: 8668. https://doi.org/10.3390/ijms23158668

Mottl A, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, et al. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis 2022;79(4):457-479. https://doi.org/10.1053/j.ajkd.2021.09.010

Van der Aart-van der Beek AB, Clegg LE, Penland RC, Boulton DW, Sjostrom CD Mentz RJ, et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes Metab 2020;22: https://doi.org/10.1111/dom.14175

Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, et al. Prediction and validation of exenatide risk marker effects on progression of renal disease: insights from EXSCEL. Diabetes Obes Metab 2020;22(5): 798-806. https://doi.org/10.1111/dom.13958

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. AMPLITUDE-O Trials Investigator. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385(10):896-907. https://doi.org/10.1056/nejmoa2108269

Leoncini, G.; Russo, E.; Bussalino, E.; Barnini, C.; Viazzi, F.; Pontremoli, R. SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. Int. J. Mol. Sci. 2021;22(9):4441. https://doi.org/10.3390/ijms22094441

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. https://doi.org/10.1056/nejmoa2024816

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dimensions


PlumX


Downloads

Download data is not yet available.